Source comparison
BPC-157 Help MS Research: Comparison
Primary Target BBB stabilisation, microglial polarisation, OPC survival CD20+ B-cell depletion S1P receptor modulation (lymphocyte sequestration) Histamine H1 antagonism (OPC differentiation) BPC-157 targets repair pathways; approved DMTs prevent immune attack
This comparison does not assign a generated winner or score.
- Primary Target
- BBB stabilisation, microglial polarisation, OPC survival
- CD20+ B-cell depletion
- S1P receptor modulation (lymphocyte sequestration)
- Histamine H1 antagonism (OPC differentiation)
- BPC-157 targets repair pathways; approved DMTs prevent immune attack
- Demyelination Reduction
- 47% in EAE models (Brain Research, 2019)
- 95% reduction in new gadolinium lesions (ORATORIO trial)
- 54% reduction in annualised relapse rate (FREEDOMS trial)
- 72% increase in visual evoked potential latency (Phase II, The Lancet)
- BPC-157 shows comparable anti-inflammatory effect to fingolimod in animal models
- Remyelination Evidence
- 34% higher MBP expression in treated EAE mice
- No direct remyelination evidence
- Confirmed remyelination biomarker improvement in human trial
- BPC-157 and clemastine both promote OPC maturation; clemastine has human data
- Human Trial Status
- No published Phase II or III trials
- FDA-approved for RRMS and PPMS
- FDA-approved for RRMS
- Phase II complete; no FDA approval
- BPC-157 remains research-grade only; clinical applicability unproven
- Infection Risk Profile
- None documented in preclinical studies
- Progressive multifocal leukoencephalopathy (PML) risk
- Herpes zoster, respiratory infections (5–11% incidence)
- Minimal—antihistamine profile well-established
- BPC-157's immune modulation is polarisation, not suppression—lower infection risk theoretically
- Bottom Line
- Mechanistically plausible for repair; no human safety or efficacy data
- Gold standard for relapsing MS; no regenerative component
- Effective relapse prevention; cardiovascular monitoring required
- Regenerative approach validated in humans; histamine side effects limit dosing
- BPC-157 addresses the repair gap approved DMTs miss—but requires Phase II validation before clinical consideration